Inebilizumab for the Treatment of Patients With Type 1 Autoimmune Pancreatitis

Inclusion Criteria: 1. A signed and dated informed consent form; 2. A commitment to adhere to the study protocol and to cooperate throughout the entire study; 3. Aged 18 years or over, regardless of gender; 4. Diagnosed with Type I AIP; 5. Indications for treatment: (1) For symptomatic participants, evidence of pancreatic involvement (e.g. obstructive jaundice, abdominal pain, lower back pain) and extra-pancreatic organ involvement (e.g. jaundice caused by bile duct stricture); (2) Asymptomatic participants with subclinical AIP that may progress to severe, irreversible damage to vital organs (e.g. persistent pancreatic mass, abnormal liver function accompanied by proximal IgG4-related sclerosing cholangitis); 6. Be able to adhere to and cooperate with study interventions, such as taking oral medication; 7. If a woman of childbearing potential, she must have used contraception for at least one month prior to screening and undertake to use contraception throughout the study period and for a specified period following the study's conclusion; Exclusion Criteria: Participants meeting any of the following criteria will be excluded from this study: 1. Women who are trying to conceive, are pregnant or are breastfeeding; 2. Those who are unable or refuse to sign the informed consent form; 3. History of mental illness; 4. Allergy to the study intervention; 5. Concurrent malignant tumours; 6. Infectious diseases such as active hepatitis or tuberculosis; 7. Concurrent uncontrolled underlying conditions, such as severe heart failure or respiratory failure.